Cardinal Health 2011 Annual Report Download - page 8

Download and view the complete annual report

Please find page 8 of the 2011 Cardinal Health annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 122

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122


As we look forward, we are excited about the future and
extremely clear on our strategic path to get there. We have
the right game plan in place, and our organization has a keen
eye on execution and the needs of our customers. We will
continue to focus on margin rates across our businesses. We
will maintain a close focus on working capital. And while we
have to weather a few lingering headwinds, we will continue to
focus on driving momentum and making sure that each of our
businesses has the market position it needs in order to compete.
Fiscal 2012 will be a noteworthy year in generics, with some
of the largest pharmaceutical products in history losing patent
exclusivity. While we can’t control the timing, we can control
how we execute on generic launches; and, we will make sure that
when opportunities are present, we execute extraordinarily well.
We will continue to deliver value to our pharmaceutical partners
as a one-stop shop for all their supply chain services needs.
Partners in this space tell us that our operational excellence
expertise, coupled with the eciencies of our National Logistics
Center, have helped drive process improvements and incremental
sales for them. And we will continue to develop customized
tools to support their promotional strategies, including
new item launches and medication adherence oerings.
We believe that the specialty solutions business is a great
opportunity for us, and we will continue to invest here.
While our broad platform is not yet to scale, we are developing
new capabilities that have been embraced by our customers
as they demand innovative solutions in a rapidly changing
environment. Our value proposition connects patients, physicians,
payors, and pharmaceutical manufacturers, with the goal to
improve access to ecient, high quality care. We have the model,
technology, expertise and resources to support each of these
stakeholders. The timing is right for this important focus on
integrated care, shared accountability and data driven outcomes.
We will also continue to invest in PET, building o of our
core capabilities and outstanding base in Single Photon
Emission Computed Tomography, our legacy low-energy
nuclear imaging activities.
We are truly excited about our move into the Chinese market.
Our business is growing well organically, but we will also look
for opportunities to build scale and geographic reach. We will
certainly be evaluating tuck-in acquisitions throughout the year,
as well as broadening the Cardinal Health portfolio in China.
We also remain focused on the way in which the delivery of
care is moving between parts of the health system — from
acute care hospitals to ambulatory centers to doctors’ oces.
And we will continue to make sure that we have the right
capabilities to serve all of those channels and the right scale
to execute our strategies. Our preferred products program
represents one of those strategies — it allows us to assist
customers in reducing their costs to serve, while reducing overall
costs in the healthcare system. We will continue to focus on
growing this important cornerstone of our Medical strategy.
“We are excited about the future and extremely clear on our strategic path
to get there. We have the right game plan in place, and our organization
has a keen eye on execution and the needs of our customers. ”